4//SEC Filing
Gallagher Cam 4
Accession 0001725160-23-000125
CIK 0001725160other
Filed
May 30, 8:00 PM ET
Accepted
May 31, 9:10 PM ET
Size
6.9 KB
Accession
0001725160-23-000125
Insider Transaction Report
Form 4
Gallagher Cam
Director
Transactions
- Sale
Common Stock
2023-05-31$26.21/sh−18,526$485,528→ 463,502 total - Sale
Common Stock
2023-05-31$26.40/sh−9,242$243,979→ 482,028 total
Footnotes (3)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
- [F2]The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.91 to $26.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001557832
Filing Metadata
- Form type
- 4
- Filed
- May 30, 8:00 PM ET
- Accepted
- May 31, 9:10 PM ET
- Size
- 6.9 KB